These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35396928)

  • 1. Nucleoside analog GS-441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid-19.
    Rasmussen HB; Thomsen R; Hansen PR
    Pharmacol Res Perspect; 2022 Apr; 10(2):e00945. PubMed ID: 35396928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice.
    Schäfer A; Martinez DR; Won JJ; Meganck RM; Moreira FR; Brown AJ; Gully KL; Zweigart MR; Conrad WS; May SR; Dong S; Kalla R; Chun K; Du Pont V; Babusis D; Tang J; Murakami E; Subramanian R; Barrett KT; Bleier BJ; Bannister R; Feng JY; Bilello JP; Cihlar T; Mackman RL; Montgomery SA; Baric RS; Sheahan TP
    Sci Transl Med; 2022 May; 14(643):eabm3410. PubMed ID: 35315683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection.
    Pitts J; Babusis D; Vermillion MS; Subramanian R; Barrett K; Lye D; Ma B; Zhao X; Riola N; Xie X; Kajon A; Lu X; Bannister R; Shi PY; Toteva M; Porter DP; Smith BJ; Cihlar T; Mackman R; Bilello JP
    Antiviral Res; 2022 Jul; 203():105329. PubMed ID: 35525335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
    Deb S; Reeves AA
    J Pharm Pharm Sci; 2021; 24():277-291. PubMed ID: 34107241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.
    Leegwater E; Moes DJAR; Bosma LBE; Ottens TH; van der Meer IM; van Nieuwkoop C; Wilms EB
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0025422. PubMed ID: 35647646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants.
    Cao L; Li Y; Yang S; Li G; Zhou Q; Sun J; Xu T; Yang Y; Liao R; Shi Y; Yang Y; Zhu T; Huang S; Ji Y; Cong F; Luo Y; Zhu Y; Luan H; Zhang H; Chen J; Liu X; Luo R; Liu L; Wang P; Yu Y; Xing F; Ke B; Zheng H; Deng X; Zhang W; Lin C; Shi M; Li CM; Zhang Y; Zhang L; Dai J; Lu H; Zhao J; Zhang X; Guo D
    Sci Transl Med; 2022 Sep; 14(661):eabm7621. PubMed ID: 35579533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19.
    Sato T; Maekawa M; Mano N; Abe T; Yamaguchi H
    J Pharm Pharm Sci; 2021; 24():227-236. PubMed ID: 34048668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys.
    Mackman RL; Kalla RV; Babusis D; Pitts J; Barrett KT; Chun K; Du Pont V; Rodriguez L; Moshiri J; Xu Y; Lee M; Lee G; Bleier B; Nguyen AQ; O'Keefe BM; Ambrosi A; Cook M; Yu J; Dempah KE; Bunyan E; Riola NC; Lu X; Liu R; Davie A; Hsiang TY; Dearing J; Vermillion M; Gale M; Niedziela-Majka A; Feng JY; Hedskog C; Bilello JP; Subramanian R; Cihlar T
    J Med Chem; 2023 Sep; 66(17):11701-11717. PubMed ID: 37596939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of itraconazole against SARS-CoV-2.
    Van Damme E; De Meyer S; Bojkova D; Ciesek S; Cinatl J; De Jonghe S; Jochmans D; Leyssen P; Buyck C; Neyts J; Van Loock M
    J Med Virol; 2021 Jul; 93(7):4454-4460. PubMed ID: 33666253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets.
    Cox RM; Wolf JD; Lieber CM; Sourimant J; Lin MJ; Babusis D; DuPont V; Chan J; Barrett KT; Lye D; Kalla R; Chun K; Mackman RL; Ye C; Cihlar T; Martinez-Sobrido L; Greninger AL; Bilello JP; Plemper RK
    Nat Commun; 2021 Nov; 12(1):6415. PubMed ID: 34741049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects.
    Tempestilli M; Ascoli Bartoli T; Benvenuto D; Stazi GV; Marchioni L; Nicastri E; Agrati C
    J Antimicrob Chemother; 2022 Sep; 77(10):2683-2687. PubMed ID: 35848782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2
    Good SS; Westover J; Jung KH; Zhou XJ; Moussa A; La Colla P; Collu G; Canard B; Sommadossi JP
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2.
    Wei D; Hu T; Zhang Y; Zheng W; Xue H; Shen J; Xie Y; Aisa HA
    Bioorg Med Chem; 2021 Sep; 46():116364. PubMed ID: 34450570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
    Agostini ML; Andres EL; Sims AC; Graham RL; Sheahan TP; Lu X; Smith EC; Case JB; Feng JY; Jordan R; Ray AS; Cihlar T; Siegel D; Mackman RL; Clarke MO; Baric RS; Denison MR
    mBio; 2018 Mar; 9(2):. PubMed ID: 29511076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
    Pitts J; Li J; Perry JK; Du Pont V; Riola N; Rodriguez L; Lu X; Kurhade C; Xie X; Camus G; Manhas S; Martin R; Shi PY; Cihlar T; Porter DP; Mo H; Maiorova E; Bilello JP
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0022222. PubMed ID: 35532238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular Uptake and Intracellular Phosphorylation of GS-441524: Implications for Its Effectiveness against COVID-19.
    Rasmussen HB; Jürgens G; Thomsen R; Taboureau O; Zeth K; Hansen PE; Hansen PR
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Pharmacokinetics and
    Wang AQ; Hagen NR; Padilha EC; Yang M; Shah P; Chen CZ; Huang W; Terse P; Sanderson P; Zheng W; Xu X
    Front Pharmacol; 2022; 13():918083. PubMed ID: 36052127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase.
    Wang Z; Yang L; Song XQ
    Front Immunol; 2022; 13():1015355. PubMed ID: 36561747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Oral Remdesivir Compared to GS-441524 for Treatment of Cats with Naturally Occurring Effusive Feline Infectious Peritonitis: A Blinded, Non-Inferiority Study.
    Cosaro E; Pires J; Castillo D; Murphy BG; Reagan KL
    Viruses; 2023 Aug; 15(8):. PubMed ID: 37632022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum.
    Reckers A; Wu AHB; Ong CM; Gandhi M; Metcalfe J; Gerona R
    J Antimicrob Chemother; 2021 Jun; 76(7):1865-1873. PubMed ID: 33864090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.